Reply
- PMID: 29680472
- PMCID: PMC7704112
- DOI: 10.1016/j.jpeds.2018.03.001
Reply
Comment on
-
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.J Pediatr. 2018 Feb;193:102-108.e1. doi: 10.1016/j.jpeds.2017.10.011. J Pediatr. 2018. PMID: 29389444 Free PMC article. Clinical Trial.
-
Pantoprazole pharmacokinetics in obese children: normalized to lean or ideal weight?J Pediatr. 2018 Jul;198:327. doi: 10.1016/j.jpeds.2018.02.066. Epub 2018 Apr 19. J Pediatr. 2018. PMID: 29681449 No abstract available.
References
-
- Ward RM, Kearns GL, Tammara B, Bishop P, O’Gorman MA, James LP, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2011;51:876–87. - PMC - PubMed
-
- World Health Organization. Growth reference data for 5–19 years. http://www.who.int/growthref/en/. Accessed February 19, 2018.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical